Study #2023-0364
A phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of intravenously administered KT-253 in adult patients with high grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma, Myelofibrosis and Advanced Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
KT-253
Description
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute lymphocytic leukemia (ALL), R/R lymphoma, myelofibrosis, and R/R solid tumors. The study will identify the pharmacologically optimal dose(s) (MTD) of KT-253 as the recommended Phase 2 dose (RP2D), based on all safety, PK, PD, and efficacy data.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
Study phase:
Phase I
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-833-391-3015
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.